AR055009A1 - Compuesto profarmaco de amida de gemcitabina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento - Google Patents
Compuesto profarmaco de amida de gemcitabina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamentoInfo
- Publication number
- AR055009A1 AR055009A1 ARP050105271A ARP050105271A AR055009A1 AR 055009 A1 AR055009 A1 AR 055009A1 AR P050105271 A ARP050105271 A AR P050105271A AR P050105271 A ARP050105271 A AR P050105271A AR 055009 A1 AR055009 A1 AR 055009A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- manufacture
- pharmaceutical composition
- gemcitabine
- cancer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 229960005277 gemcitabine Drugs 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 241000670727 Amida Species 0.000 title 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 4
- 239000013078 crystal Substances 0.000 abstract 2
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000017604 Hodgkin disease Diseases 0.000 abstract 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 abstract 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 206010042971 T-cell lymphoma Diseases 0.000 abstract 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- -1 gemcitabine amide Chemical class 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63742204P | 2004-12-17 | 2004-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055009A1 true AR055009A1 (es) | 2007-08-01 |
Family
ID=36168678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050105271A AR055009A1 (es) | 2004-12-17 | 2005-12-15 | Compuesto profarmaco de amida de gemcitabina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento |
Country Status (31)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA014909B1 (ru) * | 2006-06-21 | 2011-02-28 | Эли Лилли Энд Компани | Кристаллические формы пролекарства на основе амида гемцитабина, композиции на их основе и их применение |
| TWI436775B (zh) | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
| CN101525361B (zh) | 2009-04-21 | 2010-11-17 | 济南圣鲁金药物技术开发有限公司 | 基于吉西他滨结构的前药及其合成方法及应用 |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| CN102432654A (zh) * | 2011-09-26 | 2012-05-02 | 宋云龙 | 吉西他滨酰胺衍生物及其制备方法和用途 |
| CN104955458A (zh) | 2012-11-07 | 2015-09-30 | Z·索 | 取代的吉西他滨芳基酰胺类似物和使用所述类似物的治疗方法 |
| WO2014078295A1 (en) | 2012-11-13 | 2014-05-22 | BoYen Therapeutics, Inc. | Gemcitabine prodrugs and uses thereof |
| EP3119795A4 (en) * | 2014-03-03 | 2018-03-14 | Nucorion Pharmaceuticals, Inc. | Gemcitabine analogs |
| WO2016078160A1 (zh) * | 2014-11-17 | 2016-05-26 | 常州方圆制药有限公司 | 胞苷衍生物及其应用 |
| US10435429B2 (en) | 2017-10-03 | 2019-10-08 | Nucorion Pharmaceuticals, Inc. | 5-fluorouridine monophosphate cyclic triester compounds |
| KR102708995B1 (ko) | 2018-01-10 | 2024-09-23 | 누코리온 파마슈티컬스, 인코포레이티드. | 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물 |
| US11427550B2 (en) | 2018-01-19 | 2022-08-30 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
| KR20200118827A (ko) | 2018-02-02 | 2020-10-16 | 마베릭스 온콜로지, 잉크. | 젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트 |
| JP7598313B2 (ja) * | 2018-04-26 | 2024-12-11 | ナノメッド ホールディングス プロプライエタリー リミテッド | ジェムシタビン両親媒性プロドラッグ |
| CN108864250A (zh) * | 2018-05-29 | 2018-11-23 | 北京大学 | 一种FAPα酶敏感的吉西他滨前体药物及其制备方法和应用 |
| AU2019313484A1 (en) * | 2018-08-03 | 2021-02-18 | Cellix Bio Private Limited | Compositions and methods for the treatment of cancer |
| KR20220035143A (ko) | 2019-07-17 | 2022-03-21 | 누코리온 파마슈티컬스, 인코포레이티드. | 사이클릭 디옥시리보뉴클레오티드 화합물 |
| EP4143199B1 (en) | 2020-04-21 | 2025-11-19 | Ligand Pharmaceuticals, Inc. | Nucleotide prodrug compounds |
| PL442924A1 (pl) * | 2022-11-23 | 2024-05-27 | Politechnika Śląska | Prolek - glikokoniugat pochodny gemcytabiny, jako związek o działaniu przeciwnowotworowym, sposób otrzymywania i zastosowanie |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| US4965374A (en) * | 1987-08-28 | 1990-10-23 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| YU43193A (sh) * | 1992-06-22 | 1997-01-08 | Eli Lilly And Company | 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi |
| RU2131880C1 (ru) * | 1992-06-22 | 1999-06-20 | Эли Лилли Энд Компани | Способ получения обогащенных бета-аномером нуклеозидов |
| GB2321454A (en) * | 1997-01-24 | 1998-07-29 | Norsk Hydro As | Gemcitabine esters and amides |
| NZ336676A (en) * | 1997-01-24 | 2000-01-28 | Norsk Hydro As | Gemcitabine esters or amides useful as anti-cancer and anti-viral agents |
| US6624142B2 (en) * | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| US5965119A (en) * | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
| US6376470B1 (en) * | 1999-09-23 | 2002-04-23 | Enzon, Inc. | Polymer conjugates of ara-C and ara-C derivatives |
| EP1567169A4 (en) * | 2002-11-04 | 2009-10-21 | Xenoport Inc | GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
| US7846436B2 (en) * | 2003-11-28 | 2010-12-07 | Chemgenes Corporation | Oligonucleotides and related compounds |
-
2005
- 2005-11-30 CA CA2589850A patent/CA2589850C/en not_active Expired - Fee Related
- 2005-11-30 PL PL05852411T patent/PL1831237T3/pl unknown
- 2005-11-30 MX MX2007007228A patent/MX2007007228A/es active IP Right Grant
- 2005-11-30 SI SI200530455T patent/SI1831237T1/sl unknown
- 2005-11-30 BR BRPI0519117-3A patent/BRPI0519117A2/pt not_active IP Right Cessation
- 2005-11-30 HR HR20080529T patent/HRP20080529T3/xx unknown
- 2005-11-30 EA EA200701300A patent/EA011868B1/ru not_active IP Right Cessation
- 2005-11-30 RS RSP-2008/0502A patent/RS50629B/sr unknown
- 2005-11-30 KR KR1020077013628A patent/KR100874052B1/ko not_active Expired - Fee Related
- 2005-11-30 NZ NZ554732A patent/NZ554732A/en not_active IP Right Cessation
- 2005-11-30 EP EP05852411A patent/EP1831237B1/en not_active Expired - Lifetime
- 2005-11-30 AT AT05852411T patent/ATE405573T1/de active
- 2005-11-30 AU AU2005316922A patent/AU2005316922B2/en not_active Ceased
- 2005-11-30 JP JP2007546709A patent/JP5022911B2/ja not_active Expired - Fee Related
- 2005-11-30 CN CN2005800431815A patent/CN101080417B/zh not_active Expired - Fee Related
- 2005-11-30 ES ES05852411T patent/ES2310860T3/es not_active Expired - Lifetime
- 2005-11-30 UA UAA200706706A patent/UA86119C2/ru unknown
- 2005-11-30 DK DK05852411T patent/DK1831237T3/da active
- 2005-11-30 DE DE602005009255T patent/DE602005009255D1/de not_active Expired - Lifetime
- 2005-11-30 PT PT05852411T patent/PT1831237E/pt unknown
- 2005-11-30 US US11/719,705 patent/US7691827B2/en not_active Expired - Fee Related
- 2005-11-30 WO PCT/US2005/043125 patent/WO2006065525A1/en not_active Ceased
- 2005-12-15 PE PE2005001474A patent/PE20060771A1/es not_active Application Discontinuation
- 2005-12-15 AR ARP050105271A patent/AR055009A1/es unknown
- 2005-12-16 MY MYPI20055970A patent/MY143677A/en unknown
- 2005-12-19 TW TW094145118A patent/TWI326687B/zh not_active IP Right Cessation
-
2007
- 2007-06-04 ZA ZA200700501A patent/ZA200705019B/xx unknown
- 2007-06-04 IL IL183666A patent/IL183666A/en not_active IP Right Cessation
- 2007-06-29 NO NO20073368A patent/NO20073368L/no not_active Application Discontinuation
- 2007-07-13 MA MA30079A patent/MA29154B1/fr unknown
-
2008
- 2008-10-23 CY CY20081101194T patent/CY1108447T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR055009A1 (es) | Compuesto profarmaco de amida de gemcitabina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento | |
| CL2008001743A1 (es) | Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende. | |
| CL2010001415A1 (es) | Compuestos derivados de diazacarbazol, con actividad inhibidora de quinasa; composición farmacéutica que comprende a uno de los compuestos; y uso de la composición farmacéutica en la preparación de medicamentos para la inhibición del crecimiento celular o el tratamiento de un trastorno hiperproliferativo | |
| GT200600445A (es) | Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo. | |
| CL2008001047A1 (es) | Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata. | |
| PA8785401A1 (es) | Derivados de bencimidazol | |
| CO6270360A2 (es) | Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos | |
| EA200900155A1 (ru) | Модуляторы фармакокинетических свойств лекарственных средств | |
| CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
| ECSP099436A (es) | Acilaminopirazoles como inhibidores de fgfr | |
| MY194087A (en) | Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament | |
| CL2008002982A1 (es) | Compuestos derivados de 4,5-difenil-imidazol sustituidos por heterociclos, inhibidores mdm2; composicion farmaceutica que los comprende; proceso de preparacion de los compuestos; y uso en el tratamiento del cancer de mama, colon, pulmon o prostata. | |
| CL2007001435A1 (es) | Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer. | |
| UY32237A (es) | Compuestos de arilo con sustituyentes heterociclicos y su uso | |
| SV2011003802A (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
| CO6382089A2 (es) | Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| AR077642A1 (es) | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| AR056575A1 (es) | Compuesto de (alfa)-aminocarboxiamida que es 5-(4-[[(2-fluorofenil) metil] oxi] fenil)prolinamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para prepararlo | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| SV2010003752A (es) | Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas | |
| AR062393A1 (es) | Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor | |
| SV2009003247A (es) | Uso de compuestos de carbamato en la elaboración de medicamentos para el tratamiento de la depresión | |
| CL2007003251A1 (es) | Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |